- Home
- WLY vs NVCR Comparison
WLY vs NVCR Comparison
Compare WLY & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WLY
- NVCR
- Stock Information
- Founded
- WLY 1807
- NVCR 2000
- Country
- WLY United States
- NVCR Switzerland
- Employees
- WLY N/A
- NVCR N/A
- Industry
- WLY Books
- NVCR Medical/Dental Instruments
- Sector
- WLY Consumer Discretionary
- NVCR Health Care
- Exchange
- WLY Nasdaq
- NVCR Nasdaq
- Market Cap
- WLY 2.1B
- NVCR 1.9B
- IPO Year
- WLY N/A
- NVCR 2015
- Fundamental
- Price
- WLY $43.29
- NVCR $17.71
- Analyst Decision
- WLY
- NVCR Buy
- Analyst Count
- WLY 0
- NVCR 6
- Target Price
- WLY N/A
- NVCR $32.83
- AVG Volume (30 Days)
- WLY 709.9K
- NVCR 1.6M
- Earning Date
- WLY 06-17-2025
- NVCR 07-24-2025
- Dividend Yield
- WLY 3.26%
- NVCR N/A
- EPS Growth
- WLY N/A
- NVCR N/A
- EPS
- WLY 1.53
- NVCR N/A
- Revenue
- WLY $1,677,609,000.00
- NVCR $621,711,000.00
- Revenue This Year
- WLY $1.75
- NVCR $5.56
- Revenue Next Year
- WLY $2.40
- NVCR $9.19
- P/E Ratio
- WLY $28.29
- NVCR N/A
- Revenue Growth
- WLY N/A
- NVCR 18.27
- 52 Week Low
- WLY $36.50
- NVCR $14.17
- 52 Week High
- WLY $53.96
- NVCR $34.13
- Technical
- Relative Strength Index (RSI)
- WLY 56.41
- NVCR 51.32
- Support Level
- WLY $43.05
- NVCR $17.53
- Resistance Level
- WLY $45.64
- NVCR $18.70
- Average True Range (ATR)
- WLY 1.40
- NVCR 0.72
- MACD
- WLY 0.31
- NVCR 0.09
- Stochastic Oscillator
- WLY 74.29
- NVCR 60.56
About WLY John Wiley & Sons Inc.
John Wiley & Sons Inc is one of the world's greatest publishers and a trusted leader in research and learning. Its industry-principal content, services, platforms, and knowledge networks are tailored to meet the evolving needs of its customers and partners, including researchers, students, instructors, professionals, institutions, and corporations. The company empowers knowledge-seekers to transform today's obstacles into tomorrow's brightest opportunities. For more than two centuries, the company has been delivering on its timeless mission to unlock human potential.
About NVCR NovoCure Limited
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.